News Sentiment

ADXN sentiment intelligence

Addex Therapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.34 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

76/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+9.5% over one week, -1.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

How Addex Therapeutics Ltd (ADXN) Affects Rotational Strategy Timing

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 76/100 classification
One-week reaction 9.5% Price confirming higher
Trend fit Trend inactive -1.7% over four weeks
Fair value -26.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 32
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingView 8
GlobeNewswire 7
Stock Titan 4
Stock Traders Daily 3
Moomoo 3
GuruFocus 2
MarketBeat 2

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 19
Balance sheet 4
Analyst action 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Stock Traders Daily Direct company coverage

How Addex Therapeutics Ltd (ADXN) Affects Rotational Strategy Timing

Addex Therapeutics Ltd (ADXN) is showing strong near-term sentiment that could challenge current mid and long-term weakness. The article highlights an exceptional 69.5:1 risk-reward setup, targeting a 22.1% gain versus a 0.3% risk. AI models have generated three trading strategie

Tone
Positive 65/100
Event
Market update
Published
12 Jul 2026 08:52
Source
Stock Traders Daily
Market source Direct company coverage

Addex Announces Publication of Research Highlight Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

Addex Therapeutics announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator of mGlu7, significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The study, published in the

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 23:06
Source
Market source
Moomoo Direct company coverage

Press Release: Addex Announces Publication of Research Highlighting Therapeutic Potential of MGlu7 Modulation in Regulating Sleep and Wakefulness

Addex announced the publication of research in the British Journal of Pharmacology highlighting the therapeutic potential of mGlu7 modulation in regulating sleep and wakefulness. The research, conducted in collaboration with research institutes in Germany and France, identified a

Tone
Positive 75/100
Event
Market update
Published
08 Jul 2026 11:40
Source
Moomoo
Stock Titan Direct company coverage

mGlu7 sleep-wake study featured in Addex Therapeutics (ADXN) Form 6-K filing

Addex Therapeutics announced new preclinical research on ADX71743, an mGlu7 negative allosteric modulator, demonstrating its significant role in modulating sleep-wake regulation and stress-related neurochemistry in animal models. The findings, published in the International Journ

Tone
Positive 67/100
Event
Market update
Published
08 Jul 2026 10:10
Source
Stock Titan
The Manila Times Direct company coverage

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

Addex Therapeutics announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator of metabotropic glutamate receptor 7 (mGlu7), significantly impacts sleep-wake regulation and stress-related neurochemistry in animal mo

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 06:10
Source
The Manila Times
TradingView Direct company coverage

Price to earnings forward of Addex Therapeutics Ltd – FWB:APE

The article focuses on the "Price to earnings forward" metric for Addex Therapeutics Ltd (FWB: APE) on the Frankfurt Stock Exchange. It indicates that the market is closed and no trades have occurred for this specific financial data point during the period specified. The content

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 21:11
Source
TradingView
Stock Traders Daily Direct company coverage

(ADXN) and the Role of Price-Sensitive Allocations

This article analyzes Addex Therapeutics Ltd (NASDAQ: ADXN), highlighting weak sentiment across all horizons and suggesting a short bias. It details institutional trading strategies, including long, breakout, and short positions with specific entry, target, and stop-loss zones. T

Tone
Negative 18/100
Event
Analyst action
Published
01 Jul 2026 07:39
Source
Stock Traders Daily
Stock Titan Direct company coverage

Addex Therapeutics (ADXN) shareholders approve all AGM items and board slate

Addex Therapeutics shareholders approved all Board of Directors' proposals at the 2026 Annual General Meeting, with votes representing 29.35% of the company’s outstanding capital. This included approval of the 2025 annual report, financial statements, compensation report, and com

Tone
Positive 64/100
Event
Regulatory and legal
Published
30 Jun 2026 10:09
Source
Stock Titan
Market source Direct company coverage

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Therapeutics shareholders approved all Board of Directors' proposals at the 2026 Annual General Meeting, with 29.35% of outstanding capital represented. Key resolutions included approving financial statements, compensation reports, and re-electing board members and auditors

Tone
Positive 75/100
Event
Market update
Published
30 Jun 2026 05:09
Source
Market source
TradingView Direct company coverage

Price to earnings forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6

This article provides financial information for Addex Therapeutics Ltd Sponsored ADR (LSX:A3EXC6), focusing on its price-to-earnings forward metric. The content appears to be a stub or an incomplete financial data page from TradingView, lacking specific numerical values for the m

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 18:50
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6

The article focuses on the "Enterprise value to revenue forward" financial metric for Addex Therapeutics Ltd Sponsored ADR (LSX:A3EXC6). It presents this data from TradingView's financial overview for the company. The content appears to be a stub or a section of a larger financia

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 10:09
Source
TradingView
TradingView Direct company coverage

Addex Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ADXN)

The article provides a basic overview of Addex Therapeutics Ltd (NASDAQ:ADXN) on TradingView, focusing on its financial actuals and estimates. It highlights where users can explore reported financial data and analyst estimates across various financial statements and valuation met

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 08:09
Source
TradingView
GuruFocus Direct company coverage

Q1 2026 Addex Therapeutics Ltd Earnings Call Transcript

Addex Therapeutics (ADXN) held its Q1 2026 earnings call, detailing progress in its GABAB positive modulator program for chronic cough and repositioning dipraglurant for brain injury recovery. Despite a low cash burn rate and a strong patent position for dipraglurant, the company

Tone
Neutral 50/100
Event
Balance sheet
Published
26 Jun 2026 07:10
Source
GuruFocus
TradingView Direct company coverage

Addex Therapeutics Ltd Actuals & Estimates (SIX:ADXN)

This article provides an overview of Addex Therapeutics Ltd (SIX:ADXN) stock performance, financial actuals, and estimates. It covers current stock price, market capitalization, volatility, historical highs and lows, and upcoming earnings reports, noting that ADXN stock has seen

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6

This article provides financial data for Addex Therapeutics Ltd Sponsored ADR (LSX:A3EXC6), specifically focusing on its forward price to sales ratio. The data presented is provided by FactSet Research Systems Inc. and is accessible through TradingView.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 02:42
Source
TradingView
MarketBeat Direct company coverage

Addex Therapeutics Q1 2026 Earnings Call Transcript

Addex Therapeutics discussed its Q1 2026 results, highlighting robust preclinical data for its GABAB positive modulator in chronic cough and the repositioning of Dipraglurant for brain injury recovery. The company reported CHF 0.9 million in cash, supported by a small Q2 capital

Tone
Positive 66/100
Event
Earnings
Published
25 Jun 2026 19:10
Source
MarketBeat
Investing.com Direct company coverage

Earnings call transcript: Addex Therapeutics trims loss in Q1 2026 as cash burn stays low

Addex Therapeutics reported a narrower operating loss of CHF 0.5 million in Q1 2026, aided by reduced outsourced R&D spending, which extends its cash runway into Q4 2026. The net loss, however, widened to CHF 1.7 million due to its equity share in Neurosterix's advancing programs

Tone
Positive 64/100
Event
Balance sheet
Published
25 Jun 2026 16:42
Source
Investing.com
Benzinga Direct company coverage

Addex Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript

Addex Therapeutics reported its Q1 2026 financial results and provided a corporate update, highlighting significant progress in its GABAB Positive Modulator Cough program and the repositioning of Diproglurant for brain injury recovery. The company reported an operating loss of 0.

Tone
Positive 64/100
Event
Earnings
Published
25 Jun 2026 14:40
Source
Benzinga
AlphaStreet Direct company coverage

Addex Therapeutics Releases Q1 2026 Financial Results

Addex Therapeutics reported a Q1 2026 net loss of CHF 1.7M, an increase from the previous year, with a basic and diluted net loss per share of CHF 0.01, which remained unchanged year-over-year. Despite reducing quarterly losses, analyst sentiment remains cautious, with a consensu

Tone
Negative 28/100
Event
Earnings
Published
25 Jun 2026 10:40
Source
AlphaStreet
Stock Titan Direct company coverage

Addex Therapeutics (ADXN) posts Q1 loss and flags going-concern risk

Addex Therapeutics reported a Q1 2026 net loss of CHF 1.71 million, with cash and cash equivalents falling to CHF 0.94 million. The company's cash runway is projected only through July 2026, leading to a formal "going concern" warning due to substantial doubt about its ability to

Tone
Negative 18/100
Event
Balance sheet
Published
25 Jun 2026 09:40
Source
Stock Titan
Market source Direct company coverage

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Addex Therapeutics reported its Q1 2026 financial results, highlighting progress in its spin-out Neurosterix's Phase 1 study for NTX-253 and continued preclinical development of a GABAB PAM chronic cough candidate. The company recorded a net loss of CHF 1.7 million for the period

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 07:10
Source
Market source
TradingView Direct company coverage

ADXN: Net loss widened to CHF 1.7 million as clinical programs advanced and cash reserves declined

Addex Therapeutics (ADXN) reported a widened net loss of CHF 1.7 million in Q1 2026, with cash reserves decreasing to CHF 0.9 million. This occurred despite reduced income and expenses, as the company advanced its clinical pipeline, notably with Neurosterix's Phase 1 schizophreni

Tone
Negative 18/100
Event
Balance sheet
Published
25 Jun 2026 05:40
Source
TradingView
Moomoo Direct company coverage

Press Release: Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

Addex Therapeutics is scheduled to report its 2026 First Quarter financial results and host a conference call on June 25, 2026. Separately, Unity Software (U.US) reported its Q4 earnings with revenue increasing 35% year-over-year to $609 million, though it posted a quarterly loss

Tone
Neutral 50/100
Event
Earnings
Published
22 Jun 2026 16:40
Source
Moomoo
scanx.trade Direct company coverage

Addex Therapeutics to report Q1 2026 financial results on June 25

Addex Therapeutics announced it will report its First Quarter 2026 financial results on June 25, 2026, followed by a webcast and teleconference. CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will lead the presentation, discussing the financial results and prov

Tone
Neutral 50/100
Event
Earnings
Published
21 Jun 2026 16:12
Source
scanx.trade